Mescaline Dosage Guide

## Lethal Toxicity No human death has been documented from the pharmacological effects of mescaline alone. The estimated lethal dose in animal models (LD50 in mice: approximately 880 mg/kg intravenously) extrapolates to a dose thousands of times higher than a typical psychoactive dose in humans (200-400 mg). This places mescaline among the safest psychoactive substances in terms of acute physiological toxicity, a safety profile consistent with its use by indigenous peoples of the Americas over at least 5,700 years of documented history. ## Physiological Effects at High Doses While not lethal, high doses of mescaline (above 500-800 mg) can produce significant physiological distress: - **Severe nausea and vomiting**: Mescaline is a potent emetic. At high doses, vomiting can be prolonged and intense, creating a risk of dehydration and electrolyte imbalance, particularly in hot environments or when fluid intake is restricted. Traditional ceremonial use of peyote acknowledges purging as an expected and sometimes valued component of the experience. - **Cardiovascular effects**: Tachycardia (heart rate elevation of 20-40 bpm above baseline) and moderate hypertension can occur. In individuals with pre-existing cardiovascular conditions, these effects may be clinically significant. - **Hyperthermia**: Mescaline can elevate core body temperature, particularly at high doses or in warm environments. This risk is amplified by physical activity, dehydration, and crowded settings. - **Tremor and motor incoordination**: High doses can impair motor function significantly, increasing fall risk. ## Psychological Emergencies The primary "overdose" risk with mescaline is psychological, not physiological: - **Panic reactions**: Intense anxiety, fear of dying, and feelings of losing one's mind can occur, particularly at high doses, in unfamiliar settings, or in individuals with predisposing anxiety disorders. - **Psychotic episodes**: In individuals with a personal or family history of schizophrenia, bipolar disorder, or other psychotic disorders, mescaline can precipitate acute psychotic episodes that may require hospitalization. This represents the most serious risk and an absolute contraindication. - **Depersonalization and derealization**: Persistent feelings of unreality during or following the experience can be distressing and may require clinical attention. ## Drug Interaction Risks - **MAOIs**: Combining mescaline with monoamine oxidase inhibitors creates a risk of serotonin syndrome and hypertensive crisis. Mescaline is a phenethylamine and substrate for MAO-A; inhibiting its metabolism can dramatically increase its potency and duration. - **SSRIs and SNRIs**: Serotonin syndrome risk exists, though it is lower than with tryptamine psychedelics. SSRIs may also reduce mescaline's subjective effects. - **Lithium**: As with all serotonergic psychedelics, combination with lithium carries a risk of seizures. - **Stimulants**: Amphetamines and other stimulants can compound cardiovascular stress and psychological intensity. ## Managing Adverse Reactions If someone is having a severe reaction to mescaline: - **Reassurance**: Calm, consistent verbal reassurance ("You took a drug, it will wear off, you are safe") is the most effective first-line intervention for psychological distress. - **Environment**: Move to a quiet, dimly lit, comfortable space. Remove overstimulating inputs (loud music, crowds, bright lights). - **Hydration**: Encourage slow sipping of water or electrolyte solution, particularly if vomiting has occurred. - **Benzodiazepines**: If available, a benzodiazepine such as diazepam (10-20 mg oral) or lorazepam (1-2 mg) can reliably reduce panic and agitation without dangerous interaction. This is the standard harm reduction pharmacological intervention for psychedelic crises. - **Emergency services**: Call for medical help if there are signs of seizure, sustained high fever, chest pain, or if the person becomes unresponsive. ## Long-Term Safety Epidemiological studies of indigenous peyote use — representing the longest continuous human dataset for any psychedelic — have found no evidence of increased rates of mental illness, cognitive impairment, or neurological damage among ceremonial users. A large-scale study published in the Journal of Psychopharmacology (Halpern et al., 2005) found no evidence of psychological or cognitive deficits in Navajo members of the Native American Church who had used peyote regularly over decades.